BioGend Therapeutics Co., Ltd.(TW:6733)
NT$20.85-0.15 (-0.71%)
TW:6733
BioGend Therapeutics Co., Ltd. financials statements
NT$20.85
At close:-0.15 (-0.71%)
BioGend Therapeutics Co., Ltd. (6733) Ratios
BioGend Therapeutics Co., Ltd. Ratios
TW:6733's free cash flow for Q2 2026 was NT$-12.04M. For the 2026 fiscal year, TW:6733's free cash flow was decreased by NT$-1.07M and operating cash flow was NT$-10.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 17.60 | 21.60 | 17.32 | 17.01 | 29.24 |
| Quick Ratio | 17.03 | 21.12 | 16.96 | 16.86 | 28.88 |
| Cash Ratio | 6.03 | 6.59 | 7.15 | 5.14 | 5.43 |
| Solvency Ratio | -0.60 | -0.99 | -1.08 | -1.45 | -1.37 |
| Operating Cash Flow Ratio | -1.76 | -2.98 | -3.00 | -5.30 | -5.44 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 578.69M | NT$ 651.51M | NT$ 707.46M | NT$ 451.33M | NT$ 654.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.12 | 1.12 | 1.17 | 1.15 |
| Debt Service Coverage Ratio | -347.13 | -307.32 | -403.21 | -1672.79 | -5496.00 |
| Interest Coverage Ratio | -731.75 | -568.65 | -673.82 | -2349.49 | -8013.83 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.08 | 0.11 | 0.15 | 0.04 |
| Net Debt to EBITDA | 3.48 | 2.82 | 2.79 | 0.92 | 1.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 72.03% | 77.85% | 81.54% | 72.44% | 33.00% |
| EBIT Margin | -49.70% | -74.90% | -153.73% | -679.91% | -1556.25% |
| EBITDA Margin | -27.31% | -44.37% | -103.67% | -510.78% | -1129.68% |
| Operating Profit Margin | -49.70% | -72.93% | -160.63% | -679.91% | -1556.25% |
| Pretax Profit Margin | -46.60% | -76.50% | -153.97% | -680.20% | -1556.45% |
| Net Profit Margin | -38.05% | -69.47% | -142.23% | -586.58% | -1494.07% |
| Continuous Operations Profit Margin | -42.86% | -71.54% | -146.41% | -653.50% | -1556.45% |
| Net Income Per EBT | 81.66% | 90.82% | 92.38% | 86.24% | 95.99% |
| EBT Per EBIT | 93.77% | 104.90% | 95.85% | 100.04% | 100.01% |
| Return on Assets (ROA) | -10.38% | -12.76% | -14.88% | -22.44% | -13.53% |
| Return on Equity (ROE) | -11.40% | -14.24% | -16.61% | -26.24% | -15.60% |
| Return on Capital Employed (ROCE) | -14.18% | -13.90% | -17.58% | -27.06% | -14.44% |
| Return on Invested Capital (ROIC) | -12.98% | -12.95% | -16.66% | -25.89% | -13.81% |
| Return on Tangible Assets | -11.67% | -14.90% | -17.72% | -31.06% | -18.59% |
| Earnings Yield | -1.80% | -2.81% | -3.40% | -8.10% | -5.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.61 | 3.41 | 4.10 | 2.56 | 1.83 |
| Payables Turnover | 29.75 | 8.81 | 9.39 | 4.16 | 12.78 |
| Inventory Turnover | 3.03 | 2.33 | 1.23 | 1.77 | 0.69 |
| Fixed Asset Turnover | 5.16 | 3.38 | 1.96 | 0.92 | 1.04 |
| Asset Turnover | 0.27 | 0.18 | 0.10 | 0.04 | 0.01 |
| Working Capital Turnover Ratio | 0.35 | 0.23 | 0.17 | 0.05 | 0.01 |
| Cash Conversion Cycle | 209.25 | 222.30 | 347.70 | 261.20 | 701.38 |
| Days of Sales Outstanding | 101.06 | 106.90 | 88.93 | 142.61 | 199.02 |
| Days of Inventory Outstanding | 120.45 | 156.83 | 297.63 | 206.32 | 530.93 |
| Days of Payables Outstanding | 12.27 | 41.42 | 38.86 | 87.72 | 28.57 |
| Operating Cycle | 221.51 | 263.73 | 386.56 | 348.92 | 729.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.52 | -0.80 | -1.15 | -1.64 | -1.35 |
| Free Cash Flow Per Share | -0.53 | -0.81 | -1.37 | -1.81 | -1.36 |
| Dividend Paid and CapEx Coverage Ratio | -34.13 | -152.17 | -5.33 | -9.29 | -203.27 |
| Capital Expenditure Coverage Ratio | -34.13 | -152.17 | -5.33 | -9.29 | -203.27 |
| Operating Cash Flow Coverage Ratio | -9.68 | -10.49 | -10.60 | -10.70 | -30.95 |
| Operating Cash Flow to Sales Ratio | -0.29 | -0.59 | -1.26 | -5.37 | -14.76 |
| Free Cash Flow Yield | -1.39% | -2.40% | -3.58% | -8.21% | -5.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -55.48 | -35.42 | -29.42 | -12.35 | -19.27 |
| Price-to-Sales (P/S) Ratio | 21.18 | 24.70 | 41.85 | 72.44 | 288.47 |
| Price-to-Book (P/B) Ratio | 6.34 | 5.07 | 4.89 | 3.24 | 3.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -71.86 | -41.60 | -27.92 | -12.18 | -19.45 |
| Price-to-Operating Cash Flow Ratio | -73.97 | -41.87 | -33.16 | -13.50 | -19.55 |
| Price-to-Earnings Growth (PEG) Ratio | 2.03 | 1.32 | 1.07 | -0.40 | 1.17 |
| Enterprise Value Multiple | -74.05 | -52.86 | -37.58 | -13.26 | -24.28 |
| Enterprise Value | 4.50B | 3.93B | 4.28B | 2.13B | 2.54B |
| EV to EBITDA | -74.05 | -52.86 | -37.58 | -13.26 | -24.28 |
| EV to Sales | 20.23 | 23.45 | 38.96 | 67.74 | 274.24 |
| EV to Free Cash Flow | -68.64 | -39.49 | -25.99 | -11.39 | -18.49 |
| EV to Operating Cash Flow | -70.65 | -39.75 | -30.87 | -12.62 | -18.58 |
| Tangible Book Value Per Share | 5.43 | 5.81 | 6.56 | 6.81 | 6.56 |
| Shareholders’ Equity Per Share | 6.03 | 6.64 | 7.83 | 6.82 | 8.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.06 | 0.05 | 0.04 | 0.04 |
| Revenue Per Share | 1.81 | 1.36 | 0.91 | 0.31 | 0.09 |
| Net Income Per Share | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 |
| Tax Burden | 0.82 | 0.91 | 0.92 | 0.86 | 0.96 |
| Interest Burden | 0.94 | 1.02 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.38 | 0.77 | 1.56 | 5.29 | 12.22 |
| SG&A to Revenue | 0.62 | 0.74 | 0.87 | 2.41 | 5.84 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.75 | 0.77 | 0.82 | 0.92 | 0.95 |
Currency in TWD
